

The 7th CUHK Sarcoma Masterclass 2025

20 September 2025

Organized by:

Department of Clinical Oncology, The Chinese University of Hong Kong
Department of Orthopaedics and Traumatology, Prince of Wales Hospital
CUHK Medical Centre

In collaboration with:


The Asian Sarcoma Consortium
Melanoma & Sarcoma Medical Oncology/Biotherapy Center, Sun Yat-sen University Cancer Center



Tomotherapy



Cardiac Catheterisation Laboratory



Robotic Surgery



MR Linac



Operating Theatre



Inpatient Ward



Therapick



Doctor's Lounge



CUHK Medical Centre



☎ 3946 6888

🌐 www.cuhkmc.hk

📍 9 Chak Cheung Street, Shatin, New Territories, Hong Kong

f CUHK Medical Centre

📷 @cuhkmedicalcentre

📺 CUHK Medical Centre

in CUHK Medical Centre

Contents

4	Foreword	18	Invited Abstracts
6	Programme	24	Multidisciplinary Cases Presentation and Discussion
8	Invited Faculty	27	Acknowledgements
15	Conference Co-chair		

Foreword

Welcome to the 7th CUHK Sarcoma Masterclass! To our overseas guests, welcome to Hong Kong!

The science of sarcomas has advanced rapidly in the last decade. The heterogeneity and complexity of this disease have highlighted the importance of a multidisciplinary team approach to achieve better treatment outcomes. As an academic institution and a quaternary referral centre for sarcoma care in Hong Kong, The Chinese University of Hong Kong (CUHK) and Prince of Wales Hospital (PWH) have established an Adult Sarcoma Multidisciplinary Tumor Board (MDT) since 2012. In recent years, we have continued to advance our collaborative efforts between various disciplines.

This one-day incentive and interactive workshop will comprise of both didactic lectures and case discussions on practical aspects and latest advances in multidisciplinary sarcoma management. Faculty members of this workshop are all active and experienced members of the CUHK/PWH Adult Sarcoma MDT, as well as other hospitals and institutions in Hong Kong. We are especially delighted to have Dr. David J. Papke from Harvard Medical School to join us at this year's event. Dr. Papke will share with us his insight on *Next Generation Sequencing and Next Generation Immunohistochemistry in Sarcoma Diagnostics*.

The overriding aim of this event is to promote multidisciplinary sarcoma care, and we also look forward to hearing your opinions, views and practices in your home country. We hope that this event can also provide some face-to-face and networking time between attendees, to further enhance collaborations within the Asia-Pacific region.

We are grateful to our industry partners including (in alphabetical order) Amgen Hong Kong Limited, Eisai (Hong Kong) Company Limited, Roche Diagnostics (Hong Kong) Limited and Zai Lab (Hong Kong) Limited for providing their kind support towards this masterclass, without which this event would not have been possible.

We trust that you will find today's event of great interest.

Yours sincerely,



Dr. Herbert H. F. LOONG

Co-chair, 7th CUHK Sarcoma Masterclass 2025
Clinical Associate Professor,
Department of Clinical Oncology
Medical Director (Oncology),
Phase 1 Clinical Trial Centre
The Chinese University of Hong Kong



Dr. Kwok-chuen WONG

Co-chair, 7th CUHK Sarcoma Masterclass 2025
Consultant, Department of
Orthopaedics & Traumatology
Prince of Wales Hospital



Prof. Xing ZHANG

Co-chair, 7th CUHK Sarcoma Masterclass 2025
Director, Melanoma & Sarcoma
Medical Oncology/Biotherapy
Center
Sun Yat-sen University Cancer Center

Programme

Saturday, 20th September 2025

Time	Session	Speaker(s)
08:30-09:00	Registration	
09:00-09:15	Welcome and Opening Remarks	Dr. Herbert LOONG <i>The Chinese University of Hong Kong, HKSAR, China</i> Dr. Kwok-chuen WONG <i>Prince of Wales Hospital, HKSAR, China</i> Prof. Xing ZHANG <i>Sun Yat-sen University Cancer Center, Guangzhou, China</i>
09:15-10:00	Plenary Lecture Next Generation Sequencing and Next Generation Immunohistochemistry in Sarcoma Diagnostics	Dr. David PAPKE <i>Harvard Medical School, Boston, USA</i>
10:00-10:30	Interventional Radiology in Sarcomas	Dr. Ryan LEE <i>CUHK Medical Centre, HKSAR, China</i>
10:30-11:00	Artificial Intelligence and Digital Pathology in Diagnosis and Prognostication of Sarcomas	Dr. Maximus YEUNG <i>The University of Hong Kong, HKSAR, China</i>
11:00-11:10	Coffee Break & Networking Session	
11:10-11:40	Breakout Session 1 (SarcoZania): A. Mixed Reality Demonstration & Hands-on Practice (ORT) B. CUHKMC Smart Hospital Tour C. RT Planning Demonstration and CUHKMC RT Department Visit (Oncology) D. Bone and Soft Tissue Biopsy (Radiology)	
11:40-12:10	Breakout Session 2 (SarcoZania): A. Mixed Reality Demonstration & Hands-on Practice (ORT) B. CUHKMC Smart Hospital Tour C. RT Planning Demonstration and CUHKMC RT Department Visit (Oncology) D. Bone and Soft Tissue Biopsy (Radiology)	

Time	Session	Speaker(s)
12:10-12:40	Breakout Session 3 (SarcoZania): A. Mixed Reality Demonstration & Hands-on Practice (ORT) B. CUHKMC Smart Hospital Tour C. RT Planning Demonstration and CUHKMC RT Department Visit (Oncology) D. Bone and Soft Tissue Biopsy (Radiology)	
12:40-13:40	Lunch Break & Networking Session (Café, L/F, Hyatt Regency Hong Kong, Sha Tin)	
13:40-14:10	MDT Spotlight of the Year: Orthopaedics Harnessing Immersive Technology & Mixed Reality for Precision Surgery for Sarcomas	Dr. Kwok-chuen WONG <i>Prince of Wales Hospital, HKSAR, China</i>
14:10-14:40	Experiences in Building Sarcoma Collaborations and Networks in China and Beyond	Dr. Bushu XU <i>Sun Yat-sen University Cancer Center, Guangzhou, China</i>
14:40-15:10	Updates in Paediatrics Sarcomas for the Non-Paediatric Oncologist	Dr. Shushan HOVSEPYAN <i>Yerevan State Medical University, Yerevan, Armenia</i>
15:10-15:40	Application of Patient-Reported Outcomes to Inform Sarcoma Care	Prof. Janelle YORKE and Dr. Charlotte LIU <i>The Hong Kong Polytechnic University, HKSAR, China</i>
15:40-15:50	Coffee Break & Networking Session	
15:50-17:30	Multidisciplinary Cases Presentation and Discussion	
17:30-17:45	Award Presentations and Closing Remarks	Dr. Herbert LOONG <i>The Chinese University of Hong Kong, HKSAR, China</i> Dr. Kwok-chuen WONG <i>Prince of Wales Hospital, HKSAR, China</i> Prof. Xing ZHANG <i>Sun Yat-sen University Cancer Center, Guangzhou, China</i>

Invited Faculty



Shushan HOVSEPYAN

Yerevan State Medical University, Yerevan, Armenia

Dr. Shushan Hovsepyan, MD is a pediatric oncologist from Armenia and serves as Co-Chair of the SIOP Global Health Network's Research and Innovation Working Group, and is the Innovation and Development Director at the Immune Oncology Research Institute. Dr. Hovsepyan also co-leads the European Soft Tissue Sarcoma Group's Rhabdoid Tumor Working Group and holds the position of Editor-in-Chief at OncoDaily Medical Journal. She is an Adjunct Assistant Professor at the Department of Pediatric Oncology and Hematology at Yerevan State Medical University, and Senior Vice President of P53 Inc., which oversees platforms like OncoDaily and CancerWorld.

Invited Faculty

Ryan LEE

CUHK Medical Centre, HKSAR, China

CUHKMC Titles

- Clinical Director of Radiology
- Specialist in Radiology

University Titles

- Clinical Associate Professor (honorary)
Department of Imaging and Interventional Radiology, Faculty of Medicine, CUHK
- Honorary Clinical Assistant Professor
Department of Diagnostic Radiology, LKS Faculty of Medicine, HKU

Professional Qualifications

- MB ChB (CUHK)
- FRCR
- FHKCR
- FHKAM (Radiology)

Invited Faculty



Charlotte LIU

The Hong Kong Polytechnic University, HKSAR, China

Dr. Charlotte Liu, is a Postdoctoral Fellow at the Digital Oncology Care Enhancement (DOCE) Lab, School of Nursing, The Hong Kong Polytechnic University. She completed her PhD at The Hong Kong Polytechnic University from 2021 to 2024. Dr. Liu is a registered nurse and an active nurse researcher. Her research focuses on cancer care, with a specialization in sarcoma patients, and digital health innovations. Dr. Liu has published 30 articles in esteemed international peer-reviewed journals, including the Journal of Pain and Symptom Management, Psycho-Oncology, and Sleep Medicine Reviews.

Invited Faculty



David J. PAPKE

Harvard Medical School, Boston, USA

Dr. David J. Papke is an Assistant Professor of Pathology at Harvard Medical School and an Associate Pathologist at Brigham and Women's Hospital in Boston, USA. His clinical expertise and research interests are in Soft Tissue and Gastrointestinal Pathology. Dr. Papke graduated from the University of Illinois, Urbana-Champaign, with a B.S. in Nuclear, Plasma, and Radiological Engineering (2007), Ph.D. in Neuroscience (2013), and M.D. (2016). He matriculated into the Anatomic Pathology Residency Program at Brigham and Women's Hospital, where he served as Chief Resident in 2018. Upon graduation, he undertook subspecialty training in Gastrointestinal Pathology (2020) and Soft Tissue Pathology (2021) under the mentorship of Dr. Christopher D.M. Fletcher.

Dr. Papke has been on Faculty at Harvard Medical School since 2021. He has described several new tumor types (plexiform myofibroblastoma, pseudoendocrine sarcoma, nested glomoid neoplasm, infantile sinonasal myxoma, and myxoid inflammatory myofibroblastic sarcoma) and has implemented novel diagnostic markers for clinical practice (PDGFRA, GLI1, and CYP1A1 immunohistochemistry). He has also co-authored over 60 primary research articles and book chapters, including in the New England Journal of Medicine, JAMA Oncology, PNAS, the American Journal of Surgical Pathology, and Modern Pathology, and he has been actively teaching and mentoring trainees, for which he recently was awarded the Pier F. Paci Memorial Award for excellence in teaching.

Invited Faculty



Bushu XU

Sun Yat-sen University Cancer Center, Guangzhou, China

Dr. Bushu Xu serves as an Assistant Researcher and Physician at the Melanoma and Sarcoma Medical Oncology Unit/Biotherapy Center of Sun Yat-sen University Cancer Center. Having received her training under the mentorship of Prof. Xing Zhang, she specialized in the medical management of bone and soft tissue sarcomas. Her research focuses on elucidating sarcoma pathogenesis, identifying predictive biomarkers for targeted and immunotherapy, and developing novel treatment strategies.

Dr. Xu has been actively involved in multiple clinical and basic research projects related to sarcomas and has led or contributed to several national-level grants. She has published extensively as the first/co-first author in high-impact journals and has served as a contributing editor for "*Diagnosis and Treatment of Soft Tissue Sarcomas*" and "*Chinese Expert Consensus on Medical Therapy for Soft Tissue Sarcomas*."

Furthermore, she holds the position of Secretary of the Chemoradiotherapy Group in Chinese Anti-Cancer Association Sarcoma Committee, the Guangdong Anti-Cancer Association Sarcoma Committee, and the Guangdong Clinical Medicine Association Sarcoma Committee.

Invited Faculty



Maximus YEUNG

The University of Hong Kong, HKSAR, China

Dr. Maximus Yeung graduated from The University of Hong Kong with multiple awards, distinctions and scholarships in 2014, and received his Fellowship in Pathology from the Hong Kong College of Physicians in 2021. He obtained his Master of Science degree in Genomics and Bioinformatics with Certificate of Excellence in 2020. He is currently the Clinical Assistant Professor in the Department of Pathology, School of Clinical Medicine, the University of Hong Kong. He is also the honorary associate consultant in Queen Mary Hospital.

Dr. Yeung is the director of HKU Sarcoma Research Laboratory, which focuses on discovering biomarkers important for diagnosis, prognosis, treatment targets and prediction of therapeutic responses in different sarcomas. It involves utilizing cutting-edge technologies with multiomics analysis, single-cell profiling, functional analysis with organoid culture and state-of-the-art vision deep learning algorithm in computational pathology. In this field, he has discovered multiple novel fusions in sarcomas with comprehensive multiomics analysis. He is also involved in the development of different computational pathology algorithms, such as novel multi-task graph-transformer model (MulGT), TAD-Graph and ConcepPath, with publications in top-tier journals such as NPJ Digital Medicine. He has acquired a large multi-centre database of different sarcomas with well-annotated clinical information, radiology images, histology whole slide images and multiomics data, aiming to develop multimodality deep learning algorithms to make more precise diagnostic, prognostic and therapeutic determinations in different sarcomas.

Invited Faculty



Janelle YORKE

The Hong Kong Polytechnic University, HKSAR, China

Angel S.P. Chan Lau Professor in Health and Longevity
Chair Professor of Nursing
Head, School of Nursing
The Hong Kong Polytechnic University
Hong Kong SAR, Global STEM Professor

Education and Academic Qualifications

Certificate of Advanced Study in Learning and Teaching, Imperial College London
Graduate Diploma in Nursing (Cardiothoracic), Australian Catholic University
Master of Nursing (Research), Australian Catholic University
Doctor of Philosophy, The University of Salford

Conference Co-chair



Herbert LOONG

The Chinese University of Hong Kong, HKSAR, China

Dr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Medical Director (Oncology) of the Phase 1 Clinical Trial Centre of The Chinese University of Hong Kong. Dr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology and Sarcoma Medical Oncology. He was elected as a Fellow of ASCO (FASCO) in 2024.

Dr. Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators' Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in "Asia & Rest of the World" in 2018.

In recent years, Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

Dr. Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee (IAC) and the Asia-Pacific Regional Council of ASCO. After completing his role as the Chair of the IAC of ASCO (2024-25), He current serves as the Immediate Past Chair (2025-2026). He has also served in the Membership, Education and Communications Committees of the IASLC. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. Dr. Loong is a current Steering Committee member of the Lung Cancer Policy Network (LCPN). In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Conference Co-chair



Kwok-chuen WONG

Prince of Wales Hospital, HKSAR, China

Dr. Kwok-chuen Wong, MBChB, MD (CUHK), and FRCSEd (Ortho) has specialized in orthopaedic oncology since 2004, with research interests in applying advanced technology in orthopaedics. He is currently a Consultant and Clinical Associate Professor (Honorary) and the chief of Orthopaedic Oncology, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.

He is one of the pioneers in developing computer navigation, 3D printing applications, and recently, immersive technology (mixed reality) in orthopedic oncology, and he has extensively published in this field. He specializes in resection and complex limb reconstruction in orthopedic oncology and extreme orthopedics.

Other research interests include management of giant cell tumours of bone, outcomes of tumour prostheses, and technology translation in clinical practice.

Conference Co-chair



Xing ZHANG

Sun Yat-sen University Cancer Center, Guangzhou, China

Prof. Xing Zhang, Professor, Chief Physician, and Doctoral Supervisor, serves as Director of the Melanoma and Sarcoma Medical Oncology Unit/Biotherapy Center at Sun Yat-sen University Cancer Center. Recognized as an Outstanding Young Medical Talent of Guangdong Province and a National Distinguished Physician (Exemplary Role Model), she holds key leadership roles including Chair of the Chemoradiotherapy Group under the Sarcoma Committee of Chinese Anti-Cancer Association and Chair of the Sarcoma Committee of Guangdong Clinical Medicine Society. Her pioneering research focuses on immunotherapy and molecular targeted therapy, particularly in genomic profiling, biomarker discovery, and innovative therapy development for sarcomas.

As Principal Investigator, she has led over 10 landmark clinical trials, including the first-in-human MDM2 inhibitor clinical trial for sarcomas in China and the groundbreaking TCR-T cell therapy trial for solid tumors. As a prolific scholar, she has authored high-impact publications in journals such as *Molecular Cancer*, *British Journal of Cancer*, and *Clinical Cancer Research*, and spearheaded authoritative works including “*Diagnosis and Treatment of Soft Tissue Sarcomas*” and the “*Chinese Expert Consensus on Medical Therapy for Soft Tissue Sarcomas*.”

Invited Abstracts

Next Generation Sequencing and Next Generation Immunohistochemistry in Sarcoma Diagnostics

David J. PAPKE

Harvard Medical School, Boston, USA

Accurate diagnosis is the most important first step for the management of sarcomas. While traditional histopathology is still the mainstay in accurate diagnosis, next generation sequencing (NGS) is used increasingly both to aide in diagnosis and to identify therapeutic targets. Because NGS is somewhat expensive and time-consuming, it is not practical to sequence all sarcomas in routine practice. Therefore, pathologists and oncologists have to decide whether to sequence tumors on a case-by-case basis.

Here, I will discuss our institutional approach to sequencing sarcomas, including an algorithmic framework to help guide decision-making. I will discuss “next-generation immunohistochemistry”, immunohistochemical surrogates of genetic events that can obviate the need for NGS.

Lastly, I will discuss when NGS is necessary to identify therapeutic targets or even to establish a diagnosis.

Invited Abstracts

Artificial Intelligence and Digital Pathology in Diagnosis and Prognostication of Sarcomas

Maximus YEUNG

The University of Hong Kong, HKSAR, China

Sarcomas, a diverse group of rare malignancies, pose significant diagnostic and prognostic challenges due to their heterogeneity and complex histopathology. The integration of artificial intelligence (AI) and digital pathology offers transformative potential in addressing these challenges. The rapidly evolving state-of-the-art AI-driven algorithms, leveraging deep learning and computer vision, can analyze high-resolution digital pathology images to enhance diagnostic accuracy, identify subtle morphological features, and predict clinical outcomes.

This talk explores the role of AI in assisting subtyping, detecting biomarkers, and predicting prognosis in different sarcomas. By bridging the gap between pathology and AI, this emerging synergy promises to revolutionize sarcoma care, enabling precision medicine and improving patient outcomes.

Invited Abstracts

Immersive Technology, Mixed Reality in Orthopaedic Oncology: Clinical Experience and Journey in Implementation in Public Hospitals

Kwok-chuen WONG

Prince of Wales Hospital, HKSAR, China

In orthopedic oncology, errors in surgical planning and intraoperative execution can result in positive tumor resection margins, which negatively impact oncological outcomes. When examining bone tumor patients, surgeons must mentally process and accurately overlay the patients' virtual 2D medical images and 3D bone-tumor models onto their anatomy for surgical planning. This task is especially challenging for tumors with varying extents and in regions with complex anatomy.

Mixed Reality (MR) is an immersive technology that seamlessly combines the physical and digital worlds. It allows surgeons to better understand bone tumors by overlaying 3D holograms onto actual patients before surgery. MR technology may provide a new, more accessible, and less expensive supplement to digital tools when comparing computer navigation and 3D printed guides in orthopedic oncology. I will share our clinical experience and journey in developing and integrating this emerging technology in public hospitals.

Invited Abstracts

Experiences in Building Sarcoma Collaborations and Networks in China and Beyond

Bushu XU

Sun Yat-sen University Cancer Center, Guangzhou, China

This talk will share insights and experiences in building sarcoma collaboration and networks in China and internationally. It will cover the current landscape and challenges of sarcoma diagnosis and treatment in China, strategies for fostering cross-institutional and multidisciplinary partnerships to enhance clinical research and data sharing, and the importance of multi-regional collaborations in advancing knowledge and technology.

The presentation will highlight successful case studies, key collaboration models, and future directions for strengthening sarcoma networks worldwide, ultimately aiming to improve patient outcomes and accelerate research progress.

Invited Abstracts

Updates in Paediatrics Sarcomas for the Non-Paediatric Oncologist

Shushan HOVSEPYAN

Yerevan State Medical University, Armenia

Paediatric sarcomas are rare, biologically distinct, and often aggressive tumors that require multidisciplinary, risk-adapted management. For non-paediatric oncologists, particularly those involved in the care of adolescent and young adult (AYA) patients, timely recognition and understanding of evolving diagnostic and therapeutic principles are essential.

In this presentation, I will provide a focused update on common and clinically relevant paediatric sarcomas, including rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), Ewing sarcoma, and osteosarcoma. Emphasis will be placed on recent shifts in molecular classification, the role of fusion-based diagnostics, and how these advances inform risk stratification and treatment decisions. I will also review key changes in protocols from major cooperative groups, highlight when adjuvant therapy is indicated, and outline scenarios where referral to paediatric sarcoma centers is critical. The goal is to equip non-paediatric oncologists with a practical framework to support early diagnosis, appropriate triage, and collaborative care in this complex and rapidly evolving field.

Invited Abstracts

Experiences and Needs of Patients with Sarcoma: A Qualitative Meta-Synthesis

Janelle YORKE and Charlotte LIU

The Hong Kong Polytechnic University, HKSAR, China

Sarcomas are rare, heterogeneous malignancies that disproportionately affect younger individuals and present complex physical, psychological, and social challenges. This qualitative meta-synthesis aimed to synthesize evidence on the experiences and needs of sarcoma patients by analyzing 27 studies using thematic analysis. Three themes emerged: self-perceived health challenges after diagnosis, highlighting physical and emotional difficulties; mixed experiences during social interactions, reflecting complex relationship dynamics; and unfriendliness in society towards sarcomas, emphasizing societal barriers. These findings indicate that sarcoma patients face challenges extending beyond their health condition, significantly impacting interpersonal relationships and social wellbeing, and highlight the need for tailored support and interventions.

Multidisciplinary Cases Presentation and Discussion

Case	Presenter(s)
When Rare Meets High-Risk: Therapeutic Dilemmas in Leiomyosarcoma with Concurrent Heart Failure	Dr. Sophia Waheida Binti AHMAD <i>University of Malaya Medical Centre, Kuala Lumpur, Malaysia</i>
Primary Renal Ewing Sarcoma Diagnosed Post Nephrectomy: Dilemmas in Adjuvant Treatment	Dr. Roy Christopher ANG <i>UP-Philippine General Hospital, Manila, Philippines</i>
When Benign Turns Bold: A Rare Case of Sinonasal Osteosarcoma Arising from Fibromyxoid Tumour	Dr. Mohamed Fathulzharif BIN MOHAMED HANAN <i>Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia</i>
Limb-Sparing pCR in UPS Following Neoadjuvant PD-1 and Radiotherapy	Dr. Ching-Cheng CHANG <i>National Taiwan University Hospital HsinChu Branch, Taiwan</i>
First-line Non-chemo Regimen of Nivo Plus IPI Plus Cabo for Metastatic Epithelioid Sarcoma	Dr. Cheng-Yen HSIEH <i>National Taiwan University Cancer Center, Taiwan</i>
Management Challenges in Recurrent Mesenchymal Chondrosarcoma of the Spine: Navigating Systemic Treatment after Surgery and Radiation	Dr. Patrick Nicolo Mari LOZANO <i>UP-Philippine General Hospital, Manila, Philippines</i>
Treatment of a Case of Recurrent Spindle Cell Rhabdomyosarcoma with MYOD1 Mutation	Prof. Suying LU and Prof. Yi QUE <i>Sun Yat-sen University Cancer Center, Guangzhou, China</i>
Case Discussion of a Patient with Dedifferentiated Liposarcoma	Dr. Jing YANG and Dr. Qiyan CAI <i>Sun Yat-sen University Cancer Center, Guangzhou, China</i>

Notes

[illegible]

Notes

This image shows a blank sheet of white paper with horizontal ruling lines. The lines are evenly spaced and extend across the width of the page. At the bottom of the page, there is a decorative wavy pattern consisting of several overlapping, curved shapes in shades of light blue and green. The overall appearance is that of a clean, unused piece of stationery or a notebook page.

Acknowledgements

Sponsors:



